[关键词]
[摘要]
目的 研究左归丸对衰老大鼠骨髓间充质干细胞(MSCs)成骨与成脂分化的影响。方法 通过腹腔注射D-半乳糖建模,制备衰老大鼠模型,分离培养MSCs,并诱导MSCs成骨和成脂分化。通过碱性磷酸酶(ALP)活性检测、ALP染色观察MSCs成骨分化能力,通过甘油三酯(TG)表达量和油红O染色观察MSCs成脂分化能力。结果 模型组MSCs ALP染色阳性率明显低于正常组,左归丸组MSCs染色阳性率明显高于模型组(P<0.05)。成骨诱导14 d,模型组MSCs ALP活性值明显低于正常组而左归丸组明显高于模型组(P<0.05)。油红O染色,模型组MSCs染色阳性率明显高于正常组,左归丸组MSCs染色阳性率明显低于模型组(P<0.05)。成脂诱导7 d,模型组MSCs TG表达量明显高于正常组而左归丸组MSCs TG表达量明显低于模型组(P<0.05)。结论 左归丸可促进衰老大鼠MSCs向成骨细胞分化,同时可抑制其向脂肪细胞分化。
[Key word]
[Abstract]
Objective To investigate the effect of Zuogui pills on osteogenic differentiation and adipogenic differentiation of aging rat bone marrow mesenchymal stem cells(MSCs). Methods Aging rat model was established by intraperitoneal injection of D-galactose,and then the MSCs of the model rat were isolated. Alkaline phosphatase(ALP) activity was detected and ALP stain was applied for the observation of osteogenic differentiation of MSCs,triglyceride(TG) content was detected and oil red O staining was used for evaluation of adipogenic differentiation of MSCs. Results ALP staining results showed the positive dying rate of model group was significantly lower than that of the normal group,while Zuogui pills group had obviously higher positive dying rate than the model group(P<0.05). On osteogenic differentiation day 14,ALP activity of MSCs in the model group was lower than that of the normal group but was higher in Zuogui pills group than that of the model group(P<0.05) . The results of Oil red O staining showed that the positive dying rate of model group were significantly higher than that of the normal group,but was obviously lower in Zuogui pills group than that of the model group(P<0.05). On adipogenic differentiation day 7,TG expression level of MSCs in the model group was higher than that of the normal group but was lower in Zuogui pills group than that of the model group(P<0.05). Conclusion To some extent,Zuogui pills can promote osteogenic differentiation of aging rat MSCs and inhibit their adipogenic differentiation.
[中图分类号]
R285.5
[基金项目]
国家自然科学基金(81202732,30500645);广东省普通高校重点实验室开放基金资助项目(AAF433111A27)。